No connection

Search Results

ABBV vs AVNS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AVNS
Avanos Medical, Inc.
BEARISH
Price
$13.09
Market Cap
$607.6M
Sector
Healthcare
AI Confidence
68%

Valuation

P/E Ratio
ABBV
163.63
AVNS
--
Forward P/E
ABBV
15.42
AVNS
13.78
P/B Ratio
ABBV
-146.66
AVNS
0.78
P/S Ratio
ABBV
6.5
AVNS
0.87
EV/EBITDA
ABBV
15.27
AVNS
9.0

Profitability

Gross Margin
ABBV
71.46%
AVNS
52.28%
Operating Margin
ABBV
35.5%
AVNS
0.28%
Profit Margin
ABBV
4.0%
AVNS
-67.0%
ROE
ABBV
137.96%
AVNS
-46.68%
ROA
ABBV
9.59%
AVNS
1.58%

Growth

Revenue Growth
ABBV
9.1%
AVNS
4.3%
Earnings Growth
ABBV
-88.7%
AVNS
--

Financial Health

Debt/Equity
ABBV
--
AVNS
0.17
Current Ratio
ABBV
0.72
AVNS
2.38
Quick Ratio
ABBV
0.47
AVNS
1.23

Dividends

Dividend Yield
ABBV
3.05%
AVNS
--
Payout Ratio
ABBV
490.15%
AVNS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AVNS BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with a -67% profit margin and negative ROE of -46.68%, undermining valuation appeal. While revenue growth is positive at 4.3% YoY and recent earnings surprises have been strong, the lack of sustained profitability, deteriorating insider sentiment, and poor long-term price performance (-72.6% over 5 years) raise serious concerns. The absence of Altman Z-Score and key financial data limits confidence, but current signals point to a distressed or speculative investment.

Strengths
Revenue growth of 4.3% YoY shows top-line resilience in a challenging sector environment
Gross margin of 52.28% indicates strong pricing power and cost control at the production level
Low valuation multiples: P/B of 0.78 and P/S of 0.87 suggest potential undervaluation relative to book and sales
Risks
Piotroski F-Score of 2/9 signals severe financial weakness, particularly in profitability and leverage metrics
Profit margin of -67% and ROE of -46.68% indicate deep unprofitability and inefficient use of equity
Missing Altman Z-Score prevents definitive distress assessment, but negative earnings and ROE imply high bankruptcy risk

Compare Another Pair

ABBV vs AVNS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Avanos Medical, Inc. (AVNS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile